Hoffman et al. studied 45 patients with SLE and showed that sFLC concentrations were approximately 3-fold greater than normal (Figure 35.4) . Predictably, sFLC concentrations were higher in SLE patients with renal involvement than in those with normal renal function (Figure 35.5) . Clinical scores of SLE correlated with sFLC levels, particularly when the disease was active. In a subsequent prospective study, the clinical scores (European Consensus Lupus Activity Measurement, ECLAM ) in eight patients were compared with a variety of laboratory parameters . sFLC concentrations showed a strong correlation with disease activity that was not observed for CRP or erythrocyte sedimentation rate (ESR). A larger study with 75 SLE patients also showed a strong association between ΣFLC concentrations and disease activity (as measured by the SLE Disease Activity Index, SLEDAI; p<0.001). Similar findings were reported by Garcia de Veas Silva et al. . The association of ΣFLC with disease activity was further corroborated in a study that employed a third disease activity scoring system (British Isles Lupus Assessment Group index, BILAG) .
Assessment of autoantibody production is included (directly or indirectly) in SLE disease scoring systems and ΣFLC have, unsurprisingly, been found to be higher in anti-DNA positive versus anti-DNA negative patients (n=62) . These findings were confirmed by Garcia de Veas Silva et al. . However, in a group of 11 patients , falling concentrations of FLCs were monitored after B-cell depletion with rituximab and showed a significant correlation with total IgG but not with anti-DNA titres.
In addition to renal function, a further complicating factor when interpreting sFLC concentrations in SLE patients is the potential influence of immunosuppressant treatments. In a cross-sectional study of 77 SLE patients, Jolly et al. found that the correlation of sFLC concentrations with disease activity (Physicians Global Assessment [PGA] and SLEDAI scoring) was stronger after controlling for steroid use. The authors concluded that sFLC measurement was potentially superior to anti-DNA antibody or IL-6 for disease monitoring. 
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